Shots:

• Ichnos to receive $23.42M up front & is eligible to receive additional development and commercial milestone along with royalties
• Almirall gets the global rights to develop and commercialize mAb for autoimmune diseases while Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
• Under the terms of the agreement, Almirall will assume the full cost  & will be responsible for the development and commercialization of the product for all autoimmune disease indications. ISB 880 is a fully human, high-affinity mAb that targets human IL-1RAP

Ref: Almirall | Image: Almirall